Skip to main content
Herriot Tabuteau, MD, Other MD/DO, New York, NY

Herriot Tabuteau MD


Axsome Therapeutics, Inc.

Join to View Full Profile
  • 45 Rockefeller Plaza Suite 1000New York, NY 10111

Dr. Tabuteau is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Yale School of Medicine
    Yale School of MedicineClass of 1994

Publications & Presentations

PubMed

Press Mentions

  • Pharmanovia Enters in-Licensing Agreement with Axsome Therapeutics to Market and Further Develop Sunosi® (Solriamfetol), a First-in-Class Treatment for Excessive Daytime Sleepiness (EDS) in People with Narcolepsy and Obstructive Sleep Apnoea
    Pharmanovia Enters in-Licensing Agreement with Axsome Therapeutics to Market and Further Develop Sunosi® (Solriamfetol), a First-in-Class Treatment for Excessive Daytime Sleepiness (EDS) in People with Narcolepsy and Obstructive Sleep ApnoeaFebruary 21st, 2023
  • Axsome Therapeutics (Finally) Earns Approval. Here's What's Next
    Axsome Therapeutics (Finally) Earns Approval. Here's What's NextAugust 24th, 2022
  • Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of Psychiatry
    Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of PsychiatryMay 18th, 2022
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: